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Abstract 
Understanding the foreign body response (FBR) and desiging strategies to modulate such 
responses represent a grand challenge for implant devices and biomaterials. Here we report the 
development of a microfluidic platform, i.e., the FBR-on-a-chip (FBROC) for modeling the 
cascade of events during immune cell response to implants. Our platform modeled the native 
implant microenvironment where the implants were interfaced directly with surrounding tissues, 
as well as vasculature with circulating immune cells. Our study demonstrated that the release 
of cytokines such as monocyte chemoattractant protein 1 (MCP-1) from the extracellular matrix 
(ECM)-like hydrogels in the bottom tissue chamber induced the circulating monocytes in the 
vascular channel; resulting trans-endothelial migration of these monocytes towards the 
hydrogels, thus mimicking implant-induced inflammation. Data using patient-derived 
peripheral blood mononuclear cells further revealed inter-patient differences in such foreign 
body response, highlighting the potential of this platform for monitoring FBR in a personalized 
manner. Our prototype FBROC platform provides an enabling strategy to interrogate foreign 
body response on various implants, including novel biomaterials and engineered tissue 
constructs, in a physiologically relevant and individual-specific manner. 
 
Keywords: foreign body response; immune response; implant, biomaterials; organ-on-a-chip 
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1. Introduction 
Implantable devices and biomaterials have emerged as critical solutions for various 
healthcare problems and their use in either therapeutics or for preventive healthcare is well 
established [1-6]. However, adverse immune reactions against these non-self implants in the host 
body is often a major barrier to their success [7-12]. These adverse responses can produce 
dramatic negative outcomes such as excessive inflammation leading to severe tissue damage [13, 
14]. Chronic inflammation on the other hand, can be detrimental for the long-term functionality 
of the implants eventually leading to their failure [7, 9, 10, 13]. 
These responses are orchestrated by different components of the immune system and in 
particular macrophages, have been shown to play a pivotal role in the cascade of immunological 
responses towards implants [15-19]. Tissue-residing macrophages and recruited immune cells 
(particularly neutrophils and monocytes) from the circulation are amongst the first cells that 
react to tissue injury as well as to the introduced foreign body including different types of 
implants [15, 16, 20]. One of the persistent problems around the implants, especially those that are 
non-degradable or slowly degradable (e.g., polymeric/metallic implants), is the inability of the 
macrophages to resolve inflammation, provoking their tendency to maintain in the “frustrated 
phagocytosis” state [21]. During the beginning phase of inflammatory reactions to an injury, 
there is an increase of pro-inflammatory macrophages on the site, whereas a tolerogenic 
macrophage phenotype increases after this stage and it induces the forthcoming healing stage 
and allows the resolution of inflammation [17, 18, 22]. Under certain conditions such as existence 
of a ‘foreign body’ or some pathologies, the host immune system fails to enhance 
regulatory/healing  macrophage levels and switch to the pro-healing stage, which ultimately 
leads to persistent adverse immune reactions such as the aforementioned chronic inflammation, 
tissue damage, fibrotic capsule formation, and dysfunction of the implant [17]. 
Development of strategies to properly design the implants and solutions to avoid or alleviate 
undesired foreign body response (FBR) represents one of the most critical challenges in 
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implantable medical device field. Ideally, these characterizations should be completed at an 
early stage of product development and pre-operative material optimizations [23]. Nevertheless, 
there is currently no reliable approach to determine the adverse immune responses of the human 
body to foreign implants prior to their in vivo applications. Conventional cultures of immune 
cells directly with these implants [24-26] do not capture the dynamic process of the FBR. Various 
microfluidic platforms have been recently adapted to study immunological events such as 
inflammation and immunotherapy [27-30], but they have rarely been used in screening the FBR 
to biomaterials and implants. Rodent models, including the one recently shown to recapitulate 
key aspects of human FBR [19], are expensive and low-throughput [31]. None of the existing 
approaches allow for personalized screening of the FBR to implants. Indeed, literature [32, 33] 
suggests a significant level of inter-individual variation that is driven by individual’s 
immunological profile. Therefore, there is a strong need for personalized assessment of FBR at 
low cost and in a higher-throughput/rapid manner to select the most suitable implant material 
with optimal parameters, for a given patient. 
Here, we report the development of a physiologically relevant and microscopy-friendly in 
vitro microfluidic platform, the FBR-on-a-chip (FBROC), to reproduce the dynamic effects of 
circulating immune cells on the implant occurring in FBR. The device consisted of a bottom 
tissue chamber where the implant was introduced, an endothelium to model the vacsulature 
barrier function, and a top vascular channel to populate with circulating monocytes. The 
monocyte-endothelium interaction, their trans-endothelial migration, and activation against 
titanium (Ti) microparticles were investigated under a set of different parameters including 
variations on flow, endothelium, chemoattractant, and Ti implants. Proof of concept 
experiments using human donor-derived monocytes were further performed to reveal inter-
individual differences of FBR towards Ti microparticles in our FBROC platform. 
 
2. Results and Discussion 
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Organ-on-a-chip platforms have been widely used to model the dynamic processes involved 
in the human system in vitro. The combination of biomimetic cell/extracellular matrix (ECM) 
arrangements with microfluidic devices can be used reproduce not only the tissue 
microarchitecture but also the physicochemical cues under physiologically relevant conditions 
[34-38]. As such, the organ-on-a-chip systems are demonstrated to be superior to conventional 
planar, static cell culture strategies, providing improved accuracy in predicting human 
responses to pharmaceutical compounds, chemicals/toxins, and biological species [27, 39-42]. 
In this study, we have adapted this concept to study FBR in a physiologically relevant in 
vitro setting, through the development of a multi-layered FBROC system to reproduce the 
innate immune cell interactions with implants (Figure 1a). The polydimethylsiloxane (PDMS)-
based FBROC system consists of a bottom tissue chamber where Ti microbeads were implanted 
as the foreign body.  The bottom tissue chamber possessing Ti-beads was surrounded by a ring-
channel containing GelMA hydrogel with or without monocyte chemoattractant protein-1 
(MCP-1). The top chamber possessing an inlet and an outlet mimicked the vascular space, 
where immune cells (THP-1 monocytes) were allowed to circulate using a peristaltic pump.  In 
between these two layers, a porous PET membrane was sandwiched, on top of which a 
monolayer of HUVECs was populated to model the endothelial barrier between the vascular 
lumen and the surrounding tissue. In addition, a ring-shaped PDMS spacer having the same 
interior window size of the underlying tissue chamber was placed below the PET membrane to 
provide a desired space between the endothelial layer and the bottom tissue chamber.  The 
layers were stacked together and clamped with a pair of transparent poly(methyl methacrylate) 
(PMMA) plates with screw/bolt sets to ensure hydraulic tightness, similar to the setups 
previously reported by us and others [43, 44]. Figure 1a represents the schematics of different 
layers of the FBROC device whereas Figure 1b demonstrates the top and side views of the 
actual device. 
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In a typical experimental setting, the FBROC is connected to a reservoir hosting human 
monocytes, where the fluid flow is driven by a peristaltic pump allowing the continuous 
circulation of the monocytes through the top vascular chamber (Figure 1c). The entire setup 
can be hosted in a regular cell culture incubator to ensure sufficient gas exchanges. The specific 
dimensions of the vascular chamber are indicated in Figure S1a. Optimized flow conditions 
and monocyte distribution inside the top vascular chamber of the bioreactor was obtained using 
computational fluid dynamics (CFD) simulation by COMSOL Multiphysics 3.5a (Comsol Inc., 
Burlington, MA). Generally, fluid flow inside the microchannels are considered laminar due to 
the small channel dimensions and low fluid velocity [34]. Hence, the governing equations for 
obtaining flow conditions are continuity and momentum equations, i.e., Eq. (1) and Eq. (2), 
respectively: 
𝛁 ⋅ ?⃗⃗? = 𝟎 (1) 
?⃗⃗? ∙ 𝛁𝒖⃗⃗⃗⃗  ⃗ = −
𝟏
𝝆
𝛁𝑷 + 𝛎𝛁𝟐?⃗⃗?  (2) 
, where ?⃗⃗?  is velocity vector and ρ, P, and ν are fluid density, pressure, and kinematic viscosity, 
respectively [45]. To obtain velocity distribution, Eq. (1) and Eq. (2) are solved simultaneously 
via the finite element method (FEM). RPMI used as the cell culture medium is a homogenous, 
Newtonian, and non-compressible fluid [46]. Physical properties of the fluid were considered 
physical properties of water at 37 ºC [46]. 
Monocyte distribution was obtained by calculating trajectory of the THP-1 cells suspended 
throughout the culture medium by considering equation of motion for each set of particles 
acquired from Newton second law, hence: 
𝒅
𝒅𝒕
(𝒎𝒑?⃗⃗? ) = ?⃗?  (3) 
, where mP is monocyte’s mass and ?⃗?  is total force experienced by them. The total force exerted 
on the monocytes were composed of three components: drag force, Brownian and gravity. 
Therefore, the total force in the equation of motion can be written as: 
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𝒅𝒖𝒑
𝒅𝒕
= 𝑭𝑫 + 𝒈(𝟏 −
𝝆
𝝆𝒑
) (4) 
, where 𝒖𝒑 denotes particle velocity, FD is drag force, g is the gravity acceleration, and 𝝆𝒑 is 
the monocytes density. Drag force is obtained as: 
𝑭𝑫 = 𝟑𝝅𝝁𝒖𝒓𝒆𝒍𝒅𝒑 (5) 
, where µ indicates fluid viscosity, 𝒖𝒓𝒆𝒍 = 𝒖𝒇𝒍𝒖𝒊𝒅 − 𝒖𝒑 , and 𝒅𝒑 is monocyte diameter. For 
obtaining monocyte distribution, it was assumed that the impact of the cell motion on the fluid 
flow was negligible [47]. Therefore, first-velocity field was estimated and hence, monocyte 
trajectories were computed. 
The optimal inlet velocity was obtained by taking into consideration of factors including 
shear stress imposed on both monocytes and HUVECs, velocity profile inside the channel, the 
distribution of the circulating monocytes, and the duration for the monocytes to interact and 
pass through the endothelium barrier. Average shear stress sensed by the vascular endothelial 
cells in the human body is between 5-10 dyne cm-2 [48]. It is widely acknowledged that 
hemodynamic forces have a great impact on endothelial cells and are critical for normal vessel 
wall functionalities. For example, shear stress changes the shape and orientation of the 
endothelial cells in culture; cells might not align in the direction of the flow under low shear 
stress conditions while elevated shear stress is detrimental to the cells [49]. On the other hand, 
shear stress also affects the monocyte-endothelium interactions. Monocyte rolling and arrest to 
the endothelium are influenced by both force and contact time applied to them [46, 50], where 
shear rate of 400 s-1 (translating to ~3.6 dyne cm-2 in biological medium with a viscosity of 
8.910-4 Pa-s, see Table 1) is considered as a threshold for monocyte adhesion [49]. 
Streamline distribution of the medium flow inside the vascular channel is shown in Figure 
S1b, suggesting that the flow was largely laminar. Simulation of monocyte distribution inside 
the entire vascular chamber with a density of 1  106 cells mL-1 at the optimized flow rate of 
400 µL min-1, in perspective and cross-sectional/front views, are depicted in Figure 2a and 2b, 
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respectively, indicating that the cells could be uniformly distributed across the chamber 
emulating their homogeneous distributing profiles in circulation in blood vessels in the human 
system. 
To create the functional endothelial barrier between the vascular chamber and the tissue 
chamber, HUVECs were seed on the surface of the PET membrane (3 µm in pore size) at a 
density of 7.5  104 cells cm-2. The formation of a continuous monolayer of HUVECs was 
observed after 72 h under static culture conditions. Similarly, when the HUVECs were cultured 
under dynamic condition at the flow rate of 400 µL min-1 for the same period, the continuous 
monolayer of HUVECs was formed, consistent with our previous observations [43] and literature 
[51]. The phenotype of the endothelial monolayer on the PET porous membrane was further 
characterized by immunostaining of HUVECs with endothelial biomarkers such as vascular 
endothelial (VE)-cadherin and intercellular adhesion molecule 1 (ICAM1). VE-cadherin [52] and 
ICAM1 [53] are endothelial-speciﬁc adhesion molecules that are consistently expressed on the 
membranes of and at junctions between endothelial cells. Fluorescence microscopy images of 
the immunostained endothelial monolayer formed on the PET porous membrane exhibited 
strong expression of VE-cadherin and ICAM1 under both static (Figure 2c and d, respectively) 
and dynamic (Figure 2e and f, respectively) conditions, indicating that the flow rate used did 
not have adverse effects on the function of the endothelial cells. 
The endothelialized porous PET membrane was subsequently integrated into the FBROC 
platform to evaluate the monocyte-endothelium interactions. Human THP-1 monocytes were 
suspended in a 50:50 monocyte culture medium (RPMI 1640) and endothelial growth medium 
(EGM-1).  We compared the expressions of CD80, a class of co-stimulatory receptors, on the 
monocytes under static and dynamic conditions using CD80 antibody. It has been shown that 
the freshly isolated monocytes do not express CD80 and CD80 expression is enhanced by 
stimulation in in vitro cultures [54]. Immunostaining of THP-1 monocytes with CD80 antibody 
and fluorescence microscopy analyses performed after 4 days of dynamic culture revealed the 
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expression of CD80 (Figure 2g-j), suggesting the activation and interaction of THP-1 
monocytes with the HUVECs through attachment and spreading on the endothelial barrier 
under fluid flow, possibly induced by shear stress and the rolling effect [55-57]. On the contrary, 
under static culture condition (i.e., no fluid flow) expression of CD80 by THP-1 minimum 
amount of monocytes was observed on the endothelial barrier indicating that the TPH-1 cells 
became barely activated with limited interactions of these cells with the endothelium (Figure 
2k-o). These results demonstrated the importance of creating a dynamic in vivo-mimetic 
condition since dynamic flow seems to be critical in reproducing the interactions between 
immune cells and endothelium, as widely reported [55-57]. 
We next analyzed the migration of THP-1 monocytes through the endothelial barrier. 
Specifically, compared the monocyte migration under static and dynamic conditions, as well as 
in the absence and presence of monocyte chemoattractant protein 1 (MCP-1). MCP-1 is a key 
chemokine regulating the migration/infiltration of immune cells such as monocytes and 
macrophages, and is released by the stromal tissues upon implantation of foreign materials 
during FBR [58]. To mimic such a process, we encapsulated MCP-1 in a ring of gelatin 
methacryloyl (GelMA) hydrogel at the bottom chamber of the device, surrounding the tissue 
chamber coated with Ti microbeads (Figure 3a). GelMA hydrogel is a porous and 
biocompatible material that has been used extensively in tissue engineering because it closely 
resembles some of the essential properties of the native ECM including inherent bioactivity and 
broadly tunable physicochemical behaviors [59, 60]. The release of MCP-1 from the GelMA ring 
was quantified by collecting the medium outflow from the top vascular chamber under the same 
perfusion condition in the presence of the endothelial barrier, which showed a sustained release 
profile over the 4-day period with an initial burst release in the first day (Figure 3b). 
When THP-1 monocytes pre-labeled with cell tracker red were cultured on the vascular 
channel on the top of the PET membrane with HUVECs-monolayer under the static condition 
and in the absence of MCP-1, only very few cells could transmigrate through the endothelium 
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to reach Ti microbeads at the bottom chamber at day 4 (Fig. 3c). Whereas, increased number 
of THP-1 monocytes were found to have transmigrated through the endothelium when MCP-1 
was slowly released from the GelMA ring for the same period of time (Fig. 3d). However, 
under the dynamic flow condition the transendothelial migration of THP-1 monocytes was 
significantly higher both in the presence and absence of MCP-1 when compared to those under 
static conditions (Figure 3e and 3f). The quantitative analyses of migration of THP-1 
monocytes through the endothelial barrier under different conditions have been shown in 
Figure 3g. These results were consistent with our monocyte activation results (Figure 2i-p), 
where flow was found to be an important parameter. 
The differentiation of THP-1 monocytes into M1 or M2 phenotypes was subsequently 
evaluated by immunostaining of the cells with CD80 or CD206 antibodies, respectively, after 
they have migrated through the endothelial barrier and attached onto the Ti microbeads, under 
dynamic flow condition at day 4. CD80 is M1-specific phenotype marker and thus 
overexpressed in pro-inflammatory (M1) subtype cell population whereas CD206 is M2 
phenotype marker whose expression is increased as the cells differentiate into anti-
inflammatory alternatively activated (M2) subtype cell population [61, 62]. Immunofluorescence 
studies revealed that the increased number of transendothelial migrated THP-1 cells were 
differentiated into CD80-positive cells, primarily located in the tissue chamber containing Ti 
microbeads, both in the absence (Figure 3h) and presence (Figure 3i) of MCP-1 indicating that 
the differentiation of THP-1 was almost entirely towards the pro-inflammatory M1 phenotype 
and thus confirming the recognition of the Ti microbeads as foreign body by the THP-1 cells. 
As expected, the number of monocytes migrated across the endothelial barrier and attached to 
the Ti microbeads was higher when MCP-1 was released. Cytokine quantification at Day 4 
under dynamic culture in the presence of MCP-1 further revealed the overwhelming secretion 
of the pro-inflammatory cytokine interleukin (IL)-6 reaching a value of 403±46.5 pg mL-1, 
where its baseline concentration in standard THP-1 monocyte culture has been well-shown to 
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be minimum [63]. This observation was consistent with the immunostaining results and the fact 
that IL-6 is a pro-inflammatory cytokine that is linked to pro-inflammatory responses by 
monocytes [64]. 
We finally extended our FBROC platform for studying human primary immune cell 
responses to implants. Instead of the human THP-1 monocyte cell line, we isolated primary 
human monocytes from donor-derived peripheral blood mononucler cells (PBMCs), and 
perfused these cells in the top vascular chamber of the FBROC device, containing the same Ti 
microbeads in the bottom tissue chamber. The presence of the endothelium and the dynamic 
flow seemed to be essential in activating the interactions of the human primary monocytes with 
the barrier as shown by CD206 staining on monocytes and VE-cadherin staining on HUVECs 
(Figure 4a). Similar to the results obtained with THP-1 cell line, the release of MCP-1 from 
the bottom tissue chamber had a positive effect on inducing the trans-endothelial migration of 
the human primary monocytes, as shown in both nuclei staining (Figure 4b) and in 
quantification analyses (Figure 4c). 
Similarly, the M1/M2 differentiation of the human primary monocytes was also analyzed 
and found that for the specific donor shown in Figure S2, in either absence or presence of Ti 
microbeads in the bottom tissue chamber of the bioreactor the primary monocytes expressed 
both M1- and M2-associated surface markers approximately in equal ratio, with most cells 
exhibiting double stains. The differences of M1/M2 differentiation in response to the Ti 
microbeads between the human primary monocytes and the THP-1 monocytes could possibly 
be explained by the fact that, in the cell line the expression of each marker is induced in response 
to different environmental stimuli, while in the primary cells these markers are constitutively 
expressed and the intensities of expressions change when responding to different stimuli [64-68]. 
Indeed, when we examined the FBR of the monocytes derived from three different donors, it 
was found that, interestingly, different individuals exhibited varying degrees of immune 
responses to the same Ti microbeads (Figure 4d). While two donors (Donor B and Donor C) 
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did not exhibit noticeable difference in M1/M2 differentiation of their PBMC-derived 
monocytes, one donor (Donar A) had strong pro-inflammatory reaction to the Ti microbeads 
(Figure 4e,f), clearly indicating that there is likely a ‘population spectrum’ of responses to the 
same implant possibly due to differences in receptor expressions and cytokine profiles of the 
immune cells [32, 33]. It should be noted that, this dataset achieved with human primary 
monocytes from healthy donors was different from that observed when human THP-1 monocyte 
cell line was used (which always showed pro-inflammatory phenotype). This fact further 
confirmed that the FBR is closely dependent on the specific populations of immune cells that 
confer variations in their reactions to foreign implants, which can be effectively tested on our 
FBROC platform. 
 
3. Conclusions  
In summary, we have reported the design and fabrication of multi-layered FBROC system 
to mimic the immune cell-foreign body interactions in vitro using THP-1 monocyte cells 
circulating through the topmost vascular channel, separated from the bottom tissue chamber, 
containing Ti microbeads as the foreign body material, by a PET porous membrane coated with 
a monolayer of HUVECs. The addition of MCP-1 in the GelMA hydrogel, that functions as 
ECM surrounding the Ti microbeads, stimulated the monocyte-endothelial cell interactions and 
transendothelial migration of THP-1 cells as demonstrated by the immunostaining of cell 
specific biomarkers. Similarly, we have observed that most of the transmigrated THP-1 cells 
differentiated into the pro-inflammatory M1 phenotype, and thus confirming the recognition of 
the Ti microbeads as foreign body by the THP-1 cells. In contrast to the THP-1 cell line, 
differentiation of primary human monocytes into M1 and M2 phenotypes vary from one donor 
to other, thus indicating the importance of personalized FBROC system to study the inter-
patient difference in foreign body response. Once the FBR is screened on the FBROC platform, 
methods of immunomodulation [69-72] may then be accordingly personalized to mitigate the 
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negative immune responses of the host towards the foreign body. Thus, we believe that the 
FBROC system has a potential to expand the studies of personalized FBR on vast categories of 
subjects including but not limited to, implants reported in the current work as well as 
biologically active materials and engineered tissues. 
 
4. Experimental Section 
Materials 
 Sylgard® 184 Silicone Elastomer kit was purchased from Dow Corning Corporation 
(Midland, MI, USA) and PMMA sheets were obtained from McMaster-Carr (Elmhurst, IL, 
USA) and Goodfellow (Coraopolis, PA, USA). Gelatin from porcine skin (type-A, 300 bloom), 
methacrylic anhydride, 2-hydroxy-4’-(2-hydroxyethoxy)-2-methylpropiophenone 
(photoinitiator, PI, Irgacure 2959), triton X-100, and bovine serum albumin (BSA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s phosphate-buffered saline 
(DPBS), fetal bovine serum (FBS), trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA), 
penicillin/streptomycin, 4’,6-diamidino-2-phenylindole (DAPI), Live/Dead® Viability Kit, 
PrestoBlue® Cell Viability Reagent, RPMI 1640 medium, and PET cell culture inserts were 
purchased from ThermoFisher Scientific (Waltham, MA, USA), whereas endothelial growth 
medium-2 (EGM-2) was obtained from Lonza (Walkersville, MD, USA). Medical-grade 
(Grade 2, Neyco) Ti microbeads were supplied by PROTiP Medical (Strasbourg, France). 
Primary antibodies against human VE-cadherin, ICAM-1, CD80, and CD206, as well as Alexa 
Fluor® 594- and Alexa Fluor® 555-conjugated secondary antibodies were purchased from 
Abcam (Cambridge, MA, USA). Mouse anti-human CD31 primary antibody was purchased 
from Dako (Santa Clara, CA, USA). Recombinant human CCL2/JE/MCP-1 and all enzyme-
linked immunosorbent assay (ELISA) kits were obtained from R&D Systems (Minneapolis, 
MN, USA). All other chemicals used in this study were obtained from Sigma-Aldrich unless 
otherwise noted. 
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Synthesis of GelMA 
GelMA was synthesized according to our previously published protocol [73-75], at a high 
degree of methacryloyl substitution (81.4 ± 0.4%). Briefly, 10 g of type A gelatin from porcine 
skin was dissolved in 100 mL of DPBS at 60 °C using magnetic stirrer and 8.0 mL of 
methacrylic anhydride was added drop wisely to the gelatin solution under continuous stirring 
condition. The reaction was carried out for 3 h at 50 °C and then quenched by a 5-fold dilution 
of the reaction mixture with warm DPBS (40 °C). The product obtained was dialyzed against 
distilled water at 40 °C for 7 days using 12–14 kDa cutoff dialysis tubing to remove unreacted 
methacrylic anhydride. GelMA solution was finally lyophilized and stored at room temperature 
until further use. 
 
Cell Culture 
HUVECs expressing green fluorescent protein (GFP) purchased from Angio-Proteomie 
(Boston, MA, USA) were cultured in EGM-2 while human monocytes (THP-1) obtained from 
ATCC (Manassas, VA, USA) were cultured in RPMI 1640 medium supplemented with 10 % 
(v/v) FBS and 1% (v/v) penicillin-streptomycin. The cell cultures were maintained at 37 ºC and 
5% CO2 in a standard incubator. The medium was replaced every 2–3 days and the cells cultured 
in flasks were subcultured when they reached approximately 80% conﬂuency. For on-chip 
experiments, we used a 1:1 volume mixture of the two media as the common medium, which 
we did not observe any adverse effects on either cell type. 
 
Fabrication of the FBROC device 
The FBROC device consisting of four layers was designed and fabricated as shown in 
Figure 1.  Each layer of the chip was designed using CorelDraw (Corel Corp, Ottawa, ON) and 
imported to a laser cutting system (VLS 2.30 Desktop Laser, Universal Laser Systems Inc, 
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Richmond, VA) for cutting PMMA sheets (3 mm or 1.6 mm in thickness) into desired sizes and 
patterns to serve as the molds. PDMS precursor prepared by mixing the monomer and curing 
agent at the ratio of 10:1, was then poured onto the PMMA molds, cured at 85 °C for 2 h, and 
peeled off. The top layer consisted the vascular channel for circulating immune cells and the 
bottom layer consisted the tissue chamber coated with titanium beads (d=150 µm). In between 
these two layers, a porous PET membrane of 3 µm in pore size was sandwiched, on top of 
which a monolayer of endothelial cells was populated to model the endothelial barrier between 
the vascular lumen and the surrounding tissue.  In addition, a ring-shaped PDMS spacer having 
the same internal window size of the underlying tissue chamber was placed below the PET 
menbrane. All these layers were held together tightly using a pair of PMMA (3 mm in thickness) 
clamped with sets of screws and bolts. The microfluidic chamber on top, composed of an inlet 
and an outlet, was connected to a peristaltic pump using turbo tubings thus allowing the 
circulation of THP-1 cells. 
 
Fluid dynamics modeling and simulation 
The flow velocity and shear stress profiles in the FBROC device were investigated with 3D 
CFD simulation using FEM implemented in COMSOL Multiphysics 3.5a (Comsol Inc., 
Burlington, MA). Equations of continuity (Eq. 1) and momentum (Eq. 2) were solved 
simulatanously to obtain fluid velocity distribution. Monocyte distribution was obtained by 
considering equation of motions and calculating three forces (i.e., drag, Brownian, and gravity) 
imposed on the cells via the Lagrangian method. Constants used for the simulation are provided 
in Table 1. 
 
Table 1. Parameters and constants used for modeling. 
Simulation parameter: Symbol [SI unit] Value 
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Density of the fluid: ρ [kg/m3] 1000 [46] 
8.910-4 [46] 
1077 [76] 
15 [77] 
Viscosity of the fluid: µ [Pa-s] 
Density of the monocytes: ρp [kg/m3] 
Diameter of the monocytes: dp [µm] 
 
Morphological observations 
To observe the morphology of GFP-HUVECs in the FBROC device, after 4 days of 
dynamic experiment, the device was disassembled and the GFP-HUVECs on the PET 
membrane were fixed with 4% (v/v) paraformaldehyde for 20 min. The cells were 
permeabilized with 0.1% (v/v) Triton X-100 in DPBS for 30 min and then blocked with 1%(w/v) 
BSA in DPBS, followed by F-actin staining by incubating the cells with Alexa Fluor® 594-
phalloidin (1:40 dilution in 0.1% (w/v) BSA) for 1 h at room temperature. After washing with 
DPBS, nuclei were counter-stained with DAPI for 5 min at room temperature. Finally, the cells 
were observed using AxioObserver D1 inverted fluorescence microscope (Zeiss, Thornwood, 
NY, USA). 
 
Attraction of circulating monocytes 
MCP-1 was used as a chemoattractant to attract monocytes towards the bottom tissue 
chamber containing the Ti microbeads, simulating the cytokine released by the local tissue in 
response to the foreign body material. In both static and dynamic experiments, 50 ng mL-1 of 
MCP-1 was encapsulated in the 5 w/v% GelMA hydrogel containing 0.5% w/v PI. The GelMA 
hydrogel with MCP-1 was poured into ring-shaped channel surrounding the Ti microbeads in 
the bottom tissue chamber and then crosslinked by exposing under UV light (800 mW cm-2) for 
30 s. 
 
Transendothelial migration of monocytes through HUVEC monolayers under flow 
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Migration of monocytes through the endothelium was monitored by labeling with cell 
tracker (CM Dil dye, Thermo Fisher, Waltham, MA, USA).  The cells suspended in the medium 
was first harvested by centrifuging at 200g for 5 min. Harvested cells were mixed with CM Dil 
dye solution at the concentration of 1 μL mL-1 in DPBS and incubated at 37 ºC for 5 min and 
then at 4 ºC for 15 min. The monocytes were then suspended in the medium after washing with 
DPBS for further use. During dynamic experiments, these CM Dil-stained monocytes were 
allowed to circulate continuously through the upper vascular channel within the FBROC device. 
The THP-1 cells transmigrated across the endothelium and accumulated in the tissue chamber 
were observed using the fluorescence microscope. 
 
Human primary monocytes 
Buffy coats form healthy donors were obtained from the National Blood Service (National 
Blood Service, Sheffield, UK) following ethics committee approval (2009/D055). PBMCs were 
isolated by Histopaque-1077 (Sigma-Aldrich) density gradient centrifugation. Monocytes were 
isolated from PBMCs by positive selection of CD14+ cells using the MACS magnetic cell 
separation system (Miltenyi Biotec) as described before [78, 79]. This method routinely yielded 
>95% pure monocytes as determined by flow cytometric analysis of CD14 expression. All 
methods were performed in accordance with the relevant guidelines and regulations. 
 
ELISA 
All reagents were brought to the room temperature before starting the assay. A 200-µL 
volume of standard or sample wasadded to each monoclonal MCP-1-specific antibody-
precoated 96 microplate well and incubated for 2 h at room temperature. Then each well was 
aspirated and washed three times with washing buffer. Next, a 200-µL volume of MCP-1 
conjugate (polyclonal antibody specific for human MCP-1 conjugate) was added to each well 
and incubated 1 h at room temperature, which was then followed by three washes. Stabilized 
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hydrogen peroxide and stabilized chromogen (tetramethylbenzidine) were mixed within 15 min 
of use in equal volumes to reconstitute the substrate solution. A 200-µL volume of this solution 
was added to each well and incubated for 30 min at room temperature protected from light. 
Finally, 50 µL of 2N sulfuric acid as the stop solution was added to each well. The optical 
density of each well was determined by a microplate reader (BioTek, VT, US) at 450 nm with 
540 nm as wavelength correction. Samples were run in triplicates unless otherwise stated. 
 
Immunocytochemical analyses 
To demonstrate the functions of HUVECs, the cells on the PET membrane were 
immunostained for VE-cadherin, CD31, and ICAM-1.  At designated time points, HUVECs on 
the PET membrane were washed with DPBS and ﬁxed with 4% (w/v) paraformaldehyde for 20 
min, followed by incubation with permealization buffer (0.1% (v/v) Triton X-100 in DPBS) for 
30 min at room temperature. The cells were blocked with 1% (w/v) BSA in DPBS for 1 h at 
room temperature and incubated overnight with the primary antibody (1:200 dilution) at 4 ºC. 
After washing with DPBS, the samples were incubated with the secondary antibody at 1: 200 
dilution (Alexa Fluor® 555-conjugated goat anti-rabbit for VE-cadherin and Alexa Fluor® 594-
conjugated goat anti-mouse for CD31 or ICAM-1) for 1 h at room temperature. After washing 
with DPBS, nuclei were counter-stained with DAPI and then examined under fluorescence 
microscope. Similarly, the differentiation of THP-1 monocytes or human primary monocytes 
into M1 or M2 phenotypes was evaluated by immunostaining of the cells with CD80 (1:80 
dilution) and CD206 (1:100 dilution) antibodies. For quantifying the expression ratios of 
CD80/CD206 on primary monocytes, mean fluorescence intensities of the respective channels 
were calculated using ImageJ. 
 
Statistical analysis 
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Sample sizes were 3 in all cases. Data were presented as mean ± standard deviations. 
Statistical analysis was performed using unpaired t-tests. The statistical significance was 
determined with p<0.05 and p<0.01.  
 
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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Fig. 1. Design of the FBROC device. A) Exploded schematic diagram showing the multi-layer 
structure of the bioreactor, where an endothelialized porous membrane is sandwiched in 
between a vascular channel on top and a tissue chamber at the bottom, the latter of which 
implant of Ti microbeads was placed. B) Perspective-view and side-view photographs showing 
the bioreactor in the multi-layer configuration. C) Schematic diagram showing the operation of 
the FBROC device, where immune cells are circulated from the top vascular channel of the 
bioreactor to probe their interactions with the Ti microbeads in the bottom tissue chamber 
through the endothalial barrier. 
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Fig. 2. Characterization of monocyte distribution, vascular barrier, and monocyte-
endothelium interactions. A, B) Simulated distributions of the circulating immune cells in the 
top vascular channel of the bioreactor. C-F) Immunostaining of VE-cadherin and ICAM for 
confluent HUVECs cultured under (C, D) static and (E, F) dynamic conditions on the porous 
PET membrane. G-O) THP-1 monocyte interactions with the confluent endothelium under 
static and dynamic conditions. 
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Fig. 3. FBR of THP-1 monocytes to the Ti microbeads. A) Photograph showing the GelMA 
hydrogel ring in the bottom tissue chamber for MCP-1 release. B) MCP-1 release over a 96-h 
period. (C-F) THP-1 monocyte trans-endothelial migration towards the bottom Ti microbeads 
under (C, D) static and (E, F) dynamic conditions, in the (C, E) absence and (D, F) presence of 
MCP-1. The cells were pre-labeled with cell tracker (pink) and post-labeled for nuclei (blue). 
(G) Quantifications of the number of THP-1 monocyte migration. H, I) CD80 (green)/CD206 
(red) expressions of activated THP-1 monocytes on the Ti microbeads, in the (H) absence and 
(I) presence of MCP-1, under dynamic conditions. The nuclei were counterstained in blue. The 
white dotted circles indicate the Ti microbeads. * p<0.05. 
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Fig. 4. Donor-specific FBR of patient PBMC-derived monocytes to the Ti microbeads. A) 
Monocyte/PET membrane interactions in the absence or presence of HUVECs under static or 
dynamic conditions. B) Trans-enothelial migration of monocytes onto Ti microbeads in the 
bottom tissue chamber in the absence or presence of MCP-1 under dynamic conditions. C) 
Quantification of trans-enothelial migration of monocytes onto Ti microbeads in the bottom 
tissue chamber in the absence or presence of MCP-1. d) CD206/CD80 expressions of activated 
monocytes from three different human donors on Ti microbeads in the presence of MCP-1 
under dynamic conditions. e) Quantifications of CD206 and CD80 expressions of activated 
monocytes on the Ti microbeads in the presence of MCP-1 under dynamic conditions for 
monocytes derived from three different human donors. f) Quantifications of CD206/CD80 
expression ratios of activated monocytes on the Ti microbeads in the presence of MCP-1 under 
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dynamic conditions for monocytes derived from three different human donors. * p<0.05, ** 
p<0.01. 
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Fig. S1. Characterizations of the bioreactor. A) Dimensions of the top vascular channel of 
the bioreactor. B) Flow velocity profiles in the vascular chamber of the bioreactor. 
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Fig. S2. FBR of patient-derived monocytes to Ti microbeads. CD206/CD80 expressions of 
activated monocytes at the bottom tissue chamber, in the absence or presence of Ti microbeads, 
under dynamic conditions with the release of MCP-1. 
 
 
